News

Wyeth has reported a net income of $1.198 billion, or $0.89 per diluted share, for the first quarter of 2009, compared to $1.196 billion, or $0.89 per diluted

The complaint alleges that on April 29, 2009, after the market closed, Sequenom announced that the expected launch of its SEQureDxTM Down syndrome test will be delayed because

Outlook 2009 Novo Nordisk still expects sales growth in 2009 at the level of 10% measured in local currencies. This is based on expectations of continued market penetration

Updated 2009 Financial Guidance We are updating our guidance based on our solid first-quarter performance and our Tepnel acquisition, said Herm Rosenman, the Company’s senior vice president of

As of March 31, 2009, the company’s cash, cash equivalents, investments and settlement rights associated with certain auction rate securities totaled $194.6 million. Total operating costs and expenses

NanoViricides, a nano-biopharmaceutical company, has reported that it is developing FluCide, its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown

Ocera Therapeutics, a biopharmaceutical company, has reported positive data from its Phase II study of AST-120 for the treatment of patients with low-grade hepatic encephalopathy. The study showed

Isotechnika, a biopharmaceutical company, has reported that its Essence Phase III trial of voclosporin in moderate to severe psoriasis patients successfully met the primary endpoint of superiority to

The company reported net revenues of $5.38 billion for the first quarter of 2008, a decrease of 6%, compared to $5.71 billion for the first quarter of 2008.